Sermorelin

Where Sermorelin comes from.

Sermorelin is a synthetic 29-amino-acid peptide identical in sequence to the first 29 residues of native human growth-hormone-releasing hormone (GHRH 1-29). The native GHRH peptide is 44 amino acids long; the first 29 residues comprise the receptor-binding region, and published structure-activity research established in the 1980s that this fragment retains essentially full activity at the GHRH receptor. The compound was first described in the published literature in the 1980s and has served as the canonical native-sequence GHRH research tool ever since.

Unlike CJC-1295 No DAC and other modified GHRH analogues, Sermorelin carries no stabilising substitutions. The peptide undergoes the same rapid plasma degradation by dipeptidyl peptidase-4 (DPP-4) as native full-length GHRH, with a plasma half-life of roughly two to five minutes. This rapid clearance is the property that distinguishes Sermorelin from later modified analogues in the research literature: the compound is the native-sequence reference compound against which stabilised analogues are compared.

The peptide is built by Fmoc solid-phase peptide synthesis, purified by reversed-phase HPLC, and freeze-dried. PubMed lists more than 250 papers mentioning Sermorelin or GHRH 1-29 specifically as of 2026, with the broader GHRH literature comprising thousands of papers. The compound has been the subject of clinical research in growth-hormone-deficiency contexts and has been used as a research tool in pediatric endocrinology and adult ageing-research contexts. The research-supply form is supplied for laboratory research only.

What the research looks at.

Sermorelin mechanism research starts from the GHRH receptor, the class B G-protein-coupled receptor expressed on anterior pituitary somatotrophs and at lower density on hypothalamic neurons. The peptide binds the receptor with affinity comparable to native GHRH 1-44, confirming that the C-terminal residues 30-44 of the native protein contribute to plasma stability rather than receptor engagement. Cell-culture studies have measured second-messenger activation through the canonical Gs-cAMP-PKA pathway downstream of receptor occupancy.

A second strand of research compares the native-sequence Sermorelin against modified GHRH analogues. The published comparisons show CJC-1295 No DAC, Tesamorelin, and similar stabilised analogues producing extended plasma half-life with equivalent receptor pharmacology, while Sermorelin produces a short pulse of receptor activation followed by rapid clearance. This pharmacokinetic difference is the basis on which research designs select between native and stabilised GHRH analogues for different experimental questions.

"The native GHRH 1-29 sequence in Sermorelin retains receptor activity, but its rapid plasma clearance makes it a different research tool from stabilised analogues even at the same receptor."

A third line of research uses Sermorelin in pulse-pattern research designs. Published animal and clinical studies administer Sermorelin in defined pulse-mimicking patterns to study how the temporal pattern of GHRH receptor activation affects downstream growth-hormone secretion. The native short-half-life of Sermorelin makes it suitable for pulse research in a way that long-acting analogues such as Tesamorelin or CJC-1295 No DAC are not.

Where the published research does not go in the research-supply context: laboratory research does not extend to administration to humans, off-label clinical use, or any therapeutic application. Sermorelin pharmaceutical formulations have been regulated separately under various trade names, with availability fluctuating across jurisdictions. The research-supply form is supplied for laboratory research only.